William Jang | Head of Global Business Development
BioMe, Inc.

William Jang is a biotechnology executive specializing in the development and global commercialization of microbiome-based therapeutics. He currently serves as Head of Global Business Development at BioMe, Inc., where he drives strategic partnerships, investment initiatives, and regulatory advancement for innovative live biotherapeutic products (LBPs) targeting rare diseases, cardiovascular and renal disorders, antimicrobial resistance, and immunological conditions. Before joining BioMe, Mr. Jang co-founded MicrobiotiX, where he served as Chief Strategy Officer with a focus on overseas business development. In this role, he spearheaded international collaborations, expanded global market access opportunities, and established cross-border partnerships that strengthened the company’s pipeline and commercialization potential. With a strong foundation in microbiome biology, immunology, and translational medicine, Mr. Jang has played a pivotal role in advancing BioMe’s late preclinical pipelines, including BM109, a single-strain therapeutic targeting Trimethylaminuria (TMAU) with expansion into cardiovascular and chronic kidney disease, and BM111, a consortium therapy addressing multidrug-resistant pathogens in collaboration with Celltrion, Inc. His leadership has been central to securing FDA Orphan Drug Designation, IND-enabling strategies, and clinical trial design aimed at accelerating first-in-human studies.